ZELSUVMI
Growthberdazimer
NDATOPICALGEL
Approved
Jan 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELSUVMI (berdazimer) is a topical gel approved January 2024 for dermatological use. The mechanism of action and specific indication(s) are not publicly detailed in available data. This represents a newly launched topical therapeutic with formulation-focused patent protection.
Growth8.7 years to LOE
Early-stage product in growth phase with zero competitive pressure; commercial teams are likely focused on market development, formulary access, and brand establishment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELSUVMI is a newly launched, competition-free topical product in active growth phase, creating immediate opportunities for commercial team expansion, market development roles, and brand-building positions. The 9-year patent runway provides stability for mid-career professionals, though career longevity on the brand is finite and should be evaluated against personal LOE transition planning.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.